Montag & Associates’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $484K | Buy |
3,471
+301
| +9% | +$42.2K | 0.02% | 315 |
|
|
2025
Q4 | $389K | Sell |
3,170
-9
| -0.3% | -$1.09K | 0.02% | 326 |
|
|
2025
Q3 | $353K | Buy |
3,179
+637
| +25% | +$72.4K | 0.02% | 341 |
|
|
2025
Q2 | $282K | Buy |
2,542
+142
| +6% | +$15.1K | 0.01% | 364 |
|
|
2025
Q1 | $269K | Hold |
2,400
| – | – | 0.01% | 382 |
|
|
2024
Q4 | $222K | Hold |
2,400
| – | – | 0.01% | 412 |
|
|
2024
Q3 | $201K | Hold |
2,400
| – | – | 0.01% | 424 |
|
|
2024
Q2 | $165K | Hold |
2,400
| – | – | 0.01% | 429 |
|
|
2024
Q1 | $176K | Sell |
2,400
-245
| -9% | -$18.8K | 0.01% | 429 |
|
|
2023
Q4 | $214K | Hold |
2,645
| – | – | 0.01% | 392 |
|
|
2023
Q3 | $198K | Hold |
2,645
| – | – | 0.01% | 380 |
|
|
2023
Q2 | $204K | Hold |
2,645
| – | – | 0.01% | 390 |
|
|
2023
Q1 | $219K | Sell |
2,645
-125
| -5% | -$10.4K | 0.01% | 373 |
|
|
2022
Q4 | $238K | Buy |
2,770
+800
| +41% | +$63.4K | 0.02% | 343 |
|
|
2022
Q3 | $122K | Buy |
1,970
+1,000
| +103% | +$63.1K | 0.01% | 420 |
|
|
2022
Q2 | $60K | Hold |
970
| – | – | ﹤0.01% | 507 |
|
|
2022
Q1 | $58K | Hold |
970
| – | – | ﹤0.01% | 537 |
|
|
2021
Q4 | $70K | Hold |
970
| – | – | ﹤0.01% | 527 |
|
|
2021
Q3 | $68K | Hold |
970
| – | – | ﹤0.01% | 523 |
|
|
2021
Q2 | $67K | Hold |
970
| – | – | ﹤0.01% | 515 |
|
|
2021
Q1 | $63K | Hold |
970
| – | – | ﹤0.01% | 525 |
|
|
2020
Q4 | $57K | Buy |
+970
| New | +$58.5K | ﹤0.01% | 519 |
|
|
2020
Q3 | – | Sell |
-8,899
| Closed | -$685K | – | 310 |
|
|
2020
Q2 | $685K | Buy |
8,899
+724
| +9% | +$55.5K | 0.06% | 203 |
|
|
2020
Q1 | $611K | Buy |
+8,175
| New | +$565K | 0.06% | 204 |
|
|
2019
Q2 | – | Sell |
-3,299
| Closed | -$214K | – | 309 |
|
|
2019
Q1 | $214K | Sell |
3,299
-550
| -14% | -$36.6K | 0.02% | 288 |
|
|
2018
Q4 | $241K | Sell |
3,849
-6,030
| -61% | -$421K | 0.03% | 257 |
|
|
2018
Q3 | $763K | Sell |
9,879
-26,679
| -73% | -$2.01M | 0.07% | 201 |
|
|
2018
Q2 | $2.59M | Sell |
36,558
-3,328
| -8% | -$235K | 0.27% | 97 |
|
|
2018
Q1 | $3.01M | Sell |
39,886
-20,233
| -34% | -$1.61M | 0.31% | 89 |
|
|
2017
Q4 | $4.31M | Buy |
60,119
+11,036
| +22% | +$838K | 0.42% | 75 |
|
|
2017
Q3 | $3.98M | Buy |
+49,083
| New | +$3.75M | 0.43% | 68 |
|
|
2015
Q2 | – | Sell |
-14,375
| Closed | -$1.41M | – | 249 |
|
|
2015
Q1 | $1.41M | Sell |
14,375
-5,470
| -28% | -$555K | 0.2% | 128 |
|
|
2014
Q4 | $1.87M | Sell |
19,845
-250
| -1% | -$25.9K | 0.28% | 109 |
|
|
2014
Q3 | $2.14M | Sell |
20,095
-32,532
| -62% | -$3.19M | 0.35% | 91 |
|
|
2014
Q2 | $4.36M | Buy |
+52,627
| New | +$4.1M | 0.71% | 43 |
|
Other funds holding GILD
VCM
VPM
Montag & Associates's GILD Position: Q1 2026 in Review
Montag & Associates increased its Gilead Sciences (GILD) stake by 9.5% in Q1 2026, buying an estimated $42.2K and bringing the position to 3,471 shares worth $484K. The position accounts for 0.02% of the portfolio, ranked #315.
Montag & Associates first reported a position in GILD in Q2 2014 and has held it in 35 quarters since. The position peaked at $4.36M in Q2 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Montag & Associates held 3,471 shares of Gilead Sciences worth $484K as of Q1 2026.
- Montag & Associates bought 301 Gilead Sciences shares in Q1 2026, an estimated $42.2K.
- Gilead Sciences made up 0.02% of Montag & Associates's portfolio in Q1 2026, its #315 holding.
- Montag & Associates first reported a position in Gilead Sciences in Q2 2014 and has held it in 35 quarters since.
- Montag & Associates's Gilead Sciences position peaked at $4.36M in Q2 2014.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.